Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters











Publication year range
1.
Eur J Neurol ; 27(2): 308-317, 2020 02.
Article in English | MEDLINE | ID: mdl-31465603

ABSTRACT

BACKGROUND AND PURPOSE: The goal of this study was to determine the prevalence and incidence of neuromyelitis optica spectrum disorder (NMOSD) in Hungary based on the 2015 International Panel of NMO Diagnosis (IPND) criteria. METHODS: A retrospective population-based cohort study was conducted of 6.4 million Hungarians (age ≥ 16 years) between 1 January 2006 and 31 December 2016. Possible NMOSD patients were selected via multistage re-evaluation from multiple sources. Crude and sex- and serostatus-specific prevalence (per 100 000 persons) and incidence rates (per 1 000 000 person-years) from 2006 to 2015 were estimated and age-adjusted rates were determined. RESULTS: Of 2262 study candidates, 154 NMOSD patients (age ≥ 16 years) with onset until 31 December 2016 were identified based on 2015 IPND criteria. The prevalence analysis on 1 January 2016 included 123 NMOSD living cases, resulting in a prevalence of 1.91 [95% confidence interval (CI) 1.52-2.28] per 100 000 persons. The 101 incident cases emerging from the observed 76 394 288 person-years provided an incidence rate of 1.32 (95% CI 1.08-1.61) per 1 000 000 person-years. Age-adjusted prevalence was 1.87 (95% CI 1.56-2.23) per 100 000 persons and incidence was 1.20 (95% CI 0.98-1.46) per 1 000 000 person-years. CONCLUSIONS: In this first report of a large population-based epidemiological study from an Eastern European Caucasian population using robust case validation, a greater prevalence and incidence of NMOSD was found compared to previous large studies in Caucasian populations.


Subject(s)
Neuromyelitis Optica , Adolescent , Aquaporin 4 , Cohort Studies , Humans , Hungary/epidemiology , Incidence , Neuromyelitis Optica/epidemiology , Retrospective Studies
2.
Acta Neurol Scand ; 125(6): 373-81, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21781057

ABSTRACT

BACKGROUND: A common consequence of unilateral stroke is crossed cerebellar diaschisis (CCD), a decrease in regional blood flow (CBF) and metabolism (CMRglu) in the cerebellar hemisphere contralateral to the affected cerebral hemisphere. Former studies indicated a post-stroke time-dependent relationship between the degree of CCD and the clinical status of acute and sub-acute stroke patients, but no study has been performed in post-stroke patients. OBJECTIVES: The objective of this investigation was to evaluate the quantitative correlation between the degree of CCD and the values of clinical stroke scales in post-stroke patients. MATERIALS AND METHODS: We measured with positron emission tomography (PET) regional CBF and CMRglu values in the affected cortical regions and the contralateral cerebellum in ten ischaemic post-stroke patients. Based on these quantitative parameters, the degree of diaschisis (DoD) was calculated, and the DoD values were correlated with three clinical stroke scales [Barthel Index, Orgogozo Scale and Scandinavian Neurological Scale (SNS)]. RESULTS: There were significant linear correlations between all clinical stroke scales and the CCD values (Barthel Index and Orgogozo Scale: P < 0.001, for both CBF and CMRglu; SNS: P = 0.007 and P = 0.044; CBF and CMRglu, respectively). CONCLUSIONS: The findings indicate that DoD can be used as a quantitative indicator of the functional impairments following stroke, i.e. it can serve as a potential surrogate of the severity of the damage.


Subject(s)
Brain Ischemia/physiopathology , Severity of Illness Index , Stroke/physiopathology , Aged , Brain Ischemia/diagnostic imaging , Brain Ischemia/etiology , Brain Ischemia/metabolism , Female , Humans , Male , Middle Aged , Positron-Emission Tomography , Regional Blood Flow , Registries , Stroke/complications , Stroke/diagnostic imaging , Stroke/metabolism
3.
Eur J Neurol ; 13(11): 1251-5, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17038041

ABSTRACT

As hemorrhagic transformation (HTr) is a frequent complication and can worsen the outcome of acute ischemic stroke, our aim was to assess the risk factors of HTr. Using the database of our neuropathological laboratory, 245 consecutive acute ischemic stroke patients were analyzed. An exploratory logistic regression procedure was carried out to find the best multiple model identifying the factors associated with HTr. The autopsy revealed ischemic infarct in 175 (71%) and ischemic infarct with HTr in 70 (29%) patients. Mean age was 71.5 +/- 11.4 years (mean +/- SD) and 74.8 +/- 10.2 years (mean +/- SD), respectively. The multiple model confirmed age in case of embolic stroke, and diabetes mellitus and infarct size as independent risk factors of HTr. It seems that not serum glucose level but diabetes mellitus in the case history is an independent predictor of HTr.


Subject(s)
Brain Ischemia/complications , Cerebral Hemorrhage/etiology , Stroke/complications , Aged , Aged, 80 and over , Aging , Cadaver , Cerebral Infarction/etiology , Cerebral Infarction/pathology , Databases, Factual , Diabetes Complications , Humans , Intracranial Embolism/complications , Logistic Models , Medical Records , Middle Aged , Risk Factors , Stroke/etiology
4.
Eur J Neurol ; 10(6): 609-20, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14641504

ABSTRACT

Pathologic processes affecting the brain vessels may damage cerebral vasodilatory capacity. Early detection of cerebral dysfunction plays an important role in the prevention of cerebrovascular diseases. In recent decades acetazolamide (AZ) has frequently been used for this purpose. In the present work the mechanism of action and the previous studies are reviewed. The authors conclude that AZ tests are useful in cerebrovascular research. Further investigations are recommended to prove how impaired reserve capacity and reactivity influence the stroke risk in patients and whether these tests may indicate therapeutic interventions.


Subject(s)
Acetazolamide/therapeutic use , Cerebrovascular Disorders/drug therapy , Vasodilator Agents , Aging/physiology , Animals , Cerebrovascular Disorders/physiopathology , Dose-Response Relationship, Drug , Homeostasis/physiology , Humans , Sex Characteristics , Stroke/drug therapy , Stroke/physiopathology
5.
J Nucl Med ; 42(8): 1274-80, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11483691

ABSTRACT

UNLABELLED: Endothelin (ET) is a potent mammalian vasoconstrictive peptide and a pressor agent. Its 3 isoforms, ET-1, ET-2, and ET-3, mediate several physiologic actions in several organ systems, binding to 2 major receptor subtypes: ET(A) and ET(B). This study was undertaken to evaluate [(11)C]L-753,037 [(+)-(5S,6R,7R)-2-butyl-7-[2-((2S)-2-carboxy-propyl)-4-methoxyphenyl]-5-(3,4-methylenedioxyphenyl)cyclopenteno [1,2-beta]pyridine-6-carboxylate), a new mixed ET receptor A and B antagonist, as a tracer for in vivo labeling of ET receptors in mice and a dog. METHODS: [(11)C]L-753,037 was synthesized, purified, and formulated from a normethyl precursor, L-843,974, and [(11)C]H(3)I. The tracer was studied for its in vivo kinetics, biodistribution, and ET receptor binding characteristics in mice. In the dog, PET imaging was performed to evaluate binding of [(11)C]L-753,037 to ET receptors in the heart. Specificity of binding was studied in the heart with the selective ET(A) antagonist L-753,164. RESULTS: Kinetic studies in mice showed highest tracer uptake at 5 min after injection in liver (25.0 percentage injected dose per gram [%ID/g]), kidneys (18.7 %ID/g), lungs (15.2 %ID/g), and heart (5.6 %ID/g). Initial high uptake in liver, lungs, and kidneys was followed by rapid washout during the next 10 min and a very slow clearance during the time of observation (2 h after injection). By contrast, the radioactivity in the heart remained constant over 2 h. Administration of both ET(A) (L-753,164) and mixed ET(A)/ET(B) (L-753,137) receptor antagonists resulted in dose-dependent inhibition of [(11)C]L-753,037 binding in mouse heart, lungs, and kidneys but not in the liver. Radioactivity in the brain was very low, indicating that the tracer does not cross the blood-brain barrier. In the dog, a dynamic PET study of the heart showed high tracer accumulation at 55-95 min after injection. Injection of L-753,164 at 30 min before [(11)C]L-753,037 administration led to a significant reduction in tracer binding. [(11)C]methyl triphenyl phosphonium was used as a tracer for reference images of the dog heart muscle. CONCLUSION: The results suggest that [(11)C]L-753,037 binds to ET receptors in vivo and is, therefore, a promising candidate for investigation of these receptors and their occupancy by ET receptor antagonists using PET.


Subject(s)
Endothelin Receptor Antagonists , Pyridines , Radiopharmaceuticals , Animals , Dogs , Isotope Labeling , Mice , Pyridines/pharmacokinetics , Receptor, Endothelin A , Receptor, Endothelin B , Receptors, Endothelin/metabolism , Species Specificity , Tissue Distribution , Tomography, Emission-Computed
6.
Orv Hetil ; 142(9): 443-9, 2001 Mar 04.
Article in Hungarian | MEDLINE | ID: mdl-11301903

ABSTRACT

The effect of a single-dose i.v. infusion of vinpocetine on the cerebral blood flow (CBF) and glucose metabolism of post-stroke patients was studied by measuring the regional and global cerebral metabolic rates of glucose (CMRglu) and the corresponding kinetic constants before and after treatment. Transcranial Doppler (TCD) and single photon emission tomography (SPECT) measurements were also performed. The cerebral glucose metabolism was significantly higher in the contralateral hemisphere than in the affected one before therapy. In the affected hemisphere the regional glucose metabolism was inhomogenous: relatively low values were measured in the stroke region, whereas it was increased in the peristroke region. Although a single-dose vinpocetine treatment did not affect significantly the regional or global metabolic rates of glucose, the glucose transport (both intracellular up-take and release) was strongly affected in the whole brain, in the contralateral hemisphere and in the peri-infarct area of the symptomatic hemisphere. A slightly increased (not significant, N. S.) cerebral blood flow could be observed in the contralateral and a decreased flow (N. S.) in the symptomatic hemisphere.


Subject(s)
Brain Ischemia/complications , Brain/metabolism , Neuroprotective Agents/pharmacology , Stroke/drug therapy , Stroke/metabolism , Vasodilator Agents/pharmacology , Vinca Alkaloids/pharmacology , Aged , Brain/diagnostic imaging , Brain/drug effects , Brain Ischemia/diagnostic imaging , Brain Ischemia/metabolism , Glucose/metabolism , Humans , Infusions, Intravenous , Middle Aged , Neuroprotective Agents/administration & dosage , Stroke/diagnostic imaging , Stroke/etiology , Tomography, Emission-Computed , Tomography, Emission-Computed, Single-Photon , Treatment Outcome , Vasodilator Agents/administration & dosage , Vinca Alkaloids/administration & dosage
7.
J Clin Ultrasound ; 28(3): 115-21, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10679697

ABSTRACT

PURPOSE: Because recent data are conflicting, it is not certain whether hyperlipidemia is an independent risk factor for cerebrovascular diseases. Decreased cerebrovascular reserve capacity refers to the decreased ability of the cerebral arterioles to adapt in critical conditions and probably predicts a higher risk of stroke. The aim of this study was to compare cerebrovascular reserve capacity in hyperlipidemic patients and healthy controls using transcranial Doppler sonography. METHODS: Thirty-four hyperlipidemic patients and 21 healthy controls were examined. With transcranial Doppler sonography, the mean blood flow velocity in the middle cerebral artery was registered at rest and at 5, 10, 15, and 20 minutes after intravenous administration of 1,000 mg acetazolamide. Cerebrovascular reactivity and reserve capacity were calculated from mean blood flow velocities. Various laboratory measurements were also made and assessed for correlation with resting cerebral blood flow velocity and cerebrovascular reserve capacity. RESULTS: No significant differences could be observed between controls and hyperlipidemic patients in cerebrovascular reactivity or cerebrovascular reserve capacity. No correlation was found between various laboratory measurements and resting cerebral blood flow velocity or cerebrovascular reserve capacity. CONCLUSIONS: We could not demonstrate any differences in cerebrovascular reserve capacity between hyperlipidemic patients and healthy controls. Thus, the vasodilatory ability of the cerebral arterioles seems to remain unchanged in this patient group and is not correlated with the severity of hyperlipidemia.


Subject(s)
Cerebrovascular Circulation/physiology , Hyperlipidemias/physiopathology , Middle Cerebral Artery/diagnostic imaging , Acetazolamide/administration & dosage , Adult , Blood Flow Velocity , Cerebrovascular Circulation/drug effects , Female , Humans , Hyperlipidemias/blood , Hyperlipidemias/diagnostic imaging , Injections, Intravenous , Intracranial Arteriosclerosis/diagnostic imaging , Intracranial Arteriosclerosis/physiopathology , Lipids/blood , Male , Middle Aged , Middle Cerebral Artery/drug effects , Outpatients , Retrospective Studies , Risk Factors , Ultrasonography, Doppler, Transcranial , Vasodilation
8.
J Neuroimaging ; 8(4): 197-204, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9780850

ABSTRACT

The effects of vinpocetine (Cavinton) on the cerebral glucose metabolism of chronic stroke patients are studied with positron emission tomography. The regional and global cerebral metabolic rates of glucose (CMRglu) and the kinetic constants related to them are quantified before and after single-dose intravenous vinpocetine treatment. These measurements are completed with transcranial Doppler sonography and single photon emission computed tomography to explore the possible mechanisms underlying the resulting changes in glucose uptake and metabolism in the brain. The authors' findings indicate that a single-dose vinpocetine treatment, although it does not affect significantly the regional or global metabolic rates of glucose, improves significantly the transport of glucose (both uptake and release) through the blood-brain barrier in the whole brain, the entire contralateral hemisphere, and in the brain tissue around the infarct area of the symptomatic hemisphere. These changes are in accord with increased blood flow in the entire contralateral hemisphere as well as decreased blood flow velocity and increased peripheral vessel resistance in the entire symptomatic hemisphere.


Subject(s)
Brain/metabolism , Cerebrovascular Disorders/diagnostic imaging , Glucose/metabolism , Tomography, Emission-Computed , Vinca Alkaloids/administration & dosage , Aged , Blood Flow Velocity/drug effects , Blood-Brain Barrier/drug effects , Brain/diagnostic imaging , Brain/drug effects , Cerebrovascular Circulation/drug effects , Cerebrovascular Disorders/metabolism , Cerebrovascular Disorders/physiopathology , Female , Humans , Infusions, Intravenous , Male , Middle Aged , Tomography, Emission-Computed, Single-Photon , Ultrasonography, Doppler, Transcranial , Vinca Alkaloids/pharmacology
9.
Cephalalgia ; 9(1): 53-7, 1989 Mar.
Article in English | MEDLINE | ID: mdl-2468418

ABSTRACT

A normal cell count as well as normal CSF pressure levels were found in both classic and common migraine patients during and between attacks. Total protein content was significantly lower in the migraine patients than in the controls, but no changes were found in the CSF protein fractions. The CSF 5-hydroxyindoleacetic acid level of the migraine patients proved to be higher than in the controls, whereas the homovanillic acid concentration was within the control limits.


Subject(s)
Migraine Disorders/cerebrospinal fluid , Adult , Cerebrospinal Fluid Pressure , Cerebrospinal Fluid Proteins/analysis , Female , Homovanillic Acid/cerebrospinal fluid , Humans , Hydroxyindoleacetic Acid/cerebrospinal fluid , Male , Migraine Disorders/physiopathology
10.
Clin Chim Acta ; 105(2): 195-9, 1980 Aug 04.
Article in English | MEDLINE | ID: mdl-6772353

ABSTRACT

Unconcentrated CSF and 200 times diluted serum samples from 192 patients were examined by agar electrophoresis; their albumin and transferrin content were determined simultaneously by radial immunodiffusion. Using the data on transferrin and albumin concentrations in serum and cerebrospinal fluid, the transferrin/albumin index was calculated in a similar way to the IgG/albumin index. Normally the transferrin/albumin index is 1.68 (n = 77; S.D. = 0.22). If the permeability of the blood-CSF barrier increases, the transferrin/albumin index gradually decreases to 1. If the tau-globulin fraction is increased on the agar pherogram, the transferrin/albumin index will be greater than 2.34 (mean + 3 S.D.).


Subject(s)
Serum Albumin/cerebrospinal fluid , Transferrin/cerebrospinal fluid , Electrophoresis, Agar Gel , Humans , Immunodiffusion , Serum Albumin/immunology , Transferrin/immunology
12.
Acta Med Acad Sci Hung ; 36(4): 367-73, 1979.
Article in English | MEDLINE | ID: mdl-122042

ABSTRACT

The albumin and the IgG were determined in cerebrospinal fluid (CSF) and serum samples from 312 patients by radial immunodiffusion. The correlation between the CSF/serum ratio of IgG and the CSF/serum ratio of albumin was determined by regression analysis in three groups of patients with no signs of IgG synthesis within the central nervous system. The patients were selected on the basis of the state of the blood-CSF barrier, as indicated by the ratio of serum/CSF of albumin. Using the +2 S.D. regression borderlines, the maximal amount of IgG derived from the blood and the minimal amount of IgG synthesized within the central nervous system can be calculated in CSF samples of patients with acute infections and chronic inflammatory diseases.


Subject(s)
Central Nervous System Diseases/immunology , Immunoglobulin G/cerebrospinal fluid , Albumins/cerebrospinal fluid , Blood-Brain Barrier , Humans , Immunodiffusion , Immunoglobulin G/biosynthesis , Immunoglobulin G/blood , Serum Albumin/analysis , Statistics as Topic
13.
Article in German | MEDLINE | ID: mdl-19229

ABSTRACT

Blood-gas (pO2, pCO2) and pH-changes of venous (v.jugularis interna) and arterial (A.femoralis) blood samples, furthermore glucose utilization and lactate-, pyruvate-production of brain were investigated during electroconvulsive treatment in relaxation of 45 psychotic patients. The blood-gas values and substrate concentrations were statistically evaluated and represented in a function of the characteristic phases of the postconvulsive EEG-activity. A correlation was found between the glucose metabolism of the brain and the postconvulsive recovery of EEG. The restitution of postconvulsive brain metabolism runs discontinuously in the first 12 minutes of postconvulsive state. In the phase of electric silence and periodic delta-waves the brain metabolism was shifted to anaerobic direction. During the treatment no anoxic anoxia or acidosis takes place during the seizure activity and restitution, the measurable metabolic changes are moderate and supposedly play no important role in the "effect" of treatment.


Subject(s)
Brain/metabolism , Electroconvulsive Therapy , Electroencephalography , Blood , Blood Gas Analysis , Blood Glucose/metabolism , Brain/physiology , Humans , Hydrogen-Ion Concentration , Lactates/blood , Pyruvates/blood , Seizures/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL